| Similar Articles |
|---|
 |
The Motley Fool
January 14, 2009
Brian Orelli |
ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead.   |
The Motley Fool
August 21, 2009
Brian Orelli |
ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market. |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
May 13, 2008
Brian Orelli |
Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows. |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
August 28, 2007
Brian Orelli |
FDA Makes Cows Happy The FDA approves Omrix's human-derived thrombin, which replaces a version made from cattle. |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
May 16, 2007
Mike Havrilla |
ZymoGenetics Is Poised to Stop Bleeding With shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up. |
The Motley Fool
August 23, 2007
Brian Orelli |
Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting. |
The Motley Fool
November 6, 2006
Brian Lawler |
One Step at a Time ZymoGenetics' management is still facing challenges, but so far it has proved itself worthy to investors. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
September 6, 2007
Brian Orelli |
Foolish Fantasy Football: 3 Drug Companies The pro football season kicks off tonight. Our fantasy team might just help you tear up the investing gridiron! Here's the starting lineup. Barr Pharmaceuticals... GlaxoSmithKline... etc. |
